Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,401–2,500 of 4,275
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium
Schottler, J., Randoll, N., Lucius, R., Caliebe, A., Roider, J. B., & Klettner, A. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.03.002 · Cited by 17
“The secretion of cytokines changes during cellular and organismal aging (Coppé et al., 2008; Smith and Steinle, 2007).”
BackgroundAshraf, S., Deshpande, N. R., Cheung, Q., Boakye, J., Wong, R. K., Gauthier, A. G., Parekh, M., Adhikari, Y., Melangath, G., & Jurkunas, U. V. (2024) · Communications Biology · doi:10.1038/s42003-024-07179-1 · Cited by 20
“ThemostprominentcomponentofSASPisinterleukin-6(IL-6),a pleiotropicpro-in fl ammatorycytokinewhosesecretionisshowntoincrease due to DDR-dependent senescence in a variety of cell types 92 – 94 .”
Sayers, C. M., Papandreou, I., Guttmann, D. M., Maas, N. L., Diehl, J. A., Witze, E. S., Koong, A. C., & Koumenis, C. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081810 · Cited by 16
“Increased expression of these CDKIs has been correlated to the induction of cellular senescence (Ewald et al., 2010).”
BackgroundBiliary Epithelial Apoptosis, Autophagy, and Senescence in Primary Biliary Cirrhosis
Sasaki, M., & Nakanuma, Y. (2010) · Hepatitis Research and Treatment · doi:10.1155/2010/205128 · Cited by 17
“Previous reports, including those from our group, have reported the upregulation of several cytokines and chemokines in damaged bile ducts in PBC as described above [39, 47, 56], and recent studies have disclosed that most of these factors are known to belong to SASPs [89–93].”
BackgroundResultRecent Advances in Senolysis for Age-Related Diseases
Aratani, S., & Nakanishi, M. (2023) · Physiology · doi:10.1152/physiol.00003.2023 · Cited by 19
Stress-induced cellular responses and cell death mechanisms during inflammatory cholangiopathies
Sasaki, M., & Nakanuma, Y. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.08.002 · Cited by 17
SIRT3-Mediated Mitochondrial Regulation and Driver Tissues in Systemic Aging
Šešelja, K., Šimunić, E., Sobočanec, S., Podgorski, I. I., Pinterić, M., Hadžija, M. P., Balog, T., & Belužić, R. (2025) · Genes · doi:10.3390/genes16121497 · Cited by 19
“These alterations push cells toward a senescent phenotype, characterized by irreversible growth arrest and the secretion of a complex array of pro-inflammatory and pro-fibrotic mediators known as the senescence-associated secretory phenotype (SASP) [12,13].”
Interaction of Immune and Cancer Cells
Klink, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4 · Cited by 18
Palazzo, A., Hernández‐Vargas, H., Goehrig, D., Médard, J., Vindrieux, D., Flaman, J., & Bernard, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215850 · Cited by 17
Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01740-5 · Cited by 21
Du, H., Rose, J., Bons, J., Guo, L., Valentino, T. R., Wu, F., Burton, J. B., Basisty, N., Manwaring-Mueller, M., Makhijani, P., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01507-x · Cited by 19
“1B), previously recognized as standard measures of cellular senescence [23].”
Self-citationMao, C.-C., & Cai, X. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666200422103916 · Cited by 16
Park, M. H., Choi, J. E., Kim, J.-R., & Bae, Y. K. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609795 · Cited by 16
Metabolic regulation of endothelial senescence
Le, N.-T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1232681 · Cited by 16
Therapy-induced normal tissue damage promotes breast cancer metastasis
Perkins, D. W., Steiner, I., Haider, S., Robertson, D. M., Buus, R., O’Leary, L., & Isacke, C. M. (2023) · iScience · doi:10.1016/j.isci.2023.108503 · Cited by 21
Demir, Y. D. Ş., Özdemir, A., Sucularlı, C., Benhür, E., & Ark, M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110007 · Cited by 18
Torrance, B. L., Cadar, A. N., Martin, D. E., Panier, H. A., Lorenzo, E. C., Bartley, J. M., Xu, M., & Haynes, L. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1212750 · Cited by 21
“Senescent cells also remain metabolically active and secrete a heterogenous mixture of generally proinflammatory cytokines including IL-6, TNF-α, IL1β, CCL2, as well as some profibrotic factors like TGF-β as a part of the senescence associated secretory phenotype (SASP) (Coppé et al., 2008).”
BackgroundPan, Y., Gu, Z., Lyu, Y., Yang, Y., Chung, M., Pan, X., & Cai, S. (2022) · Rejuvenation Research · doi:10.1089/rej.2022.0021 · Cited by 18
“10,17,18 Senescent cells can produce and secrete a myriad of extracellular modulators that include cytokines ( e.g., interleukin [IL]-1, IL-6), chemokines ( e.g., IL-8, CXCL1, CXCL2), extracellular matrix proteases ( e.g., matrix metalloproteinases [MMPs]), growth factors ( e.g., transforming…”
The autophagy-senescence axis as a threshold model of aging and therapeutic targeting
Bahar, M. E., Hwang, J. S., Lai, T. H., Akter, K.-M., Maulidi, R. F., & Kim, D. R. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104079 · Cited by 25
“Senes-cent cells remain metabolically active and adopt a hypersecretory state characterized by the senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines, growth factors, and proteases that disrupt tissue homeostasis [10,11].”
The Aging Adipose Organ: Lipid Redistribution, Inflammation, and Cellular Senescence
Stout, M. B., Tchkonia, T., & Kirkland, J. L. (2014) · Humana Press eBooks · doi:10.1007/978-1-62703-770-9_5 · Cited by 18
Tonnessen-Murray, C. A., Ungerleider, N., Rao, S. G., Wasylishen, A. R., Frey, W. D., & Jackson, J. G. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.003 · Cited by 15
Aryl hydrocarbon receptor blocks aging-induced senescence in the liver and fibroblast cells
Nacarino-Palma, A., Rico-Leo, E. M., Campisi, J., Ramanathan, A., González-Rico, F. J., Rejano-Gordillo, C. M., Ordiales-Talavero, A., Merino, J. M., & Fernández‐Salguero, P. M. (2022) · Aging · doi:10.18632/aging.204103 · Cited by 21
“The former cellular response to senescence is to halt proliferation of damaged cells, thus evolving as a protective and barrier mechanism against the development of cancer (Campisi and Robert, 2014; Coppe et al., 2008; Rhinn et al., 2019).”
Self-citationDRG2 Depletion Promotes Endothelial Cell Senescence and Vascular Endothelial Dysfunction
Le, A.-N., Park, S.-S., Le, M.-X., Lee, U. H., Ko, B. K., Lim, H. R., Yu, R., Choi, S. H., Lee, B. J., Ham, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052877 · Cited by 16
“To determine if DRG2 deficiency would also induce components of the SASP, levels of IL-6, CXCL10, and IFN-β1 in wild-type and DRG2−/− mLECs were measured after etoposide treatment using qPCR.”
BackgroundInfluentialTran, J. R., Zheng, X., & Zheng, Y. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-06-0462 · Cited by 16
“Of interest, both Lb1 reduction and increased secretion of proinflammatory cytokines and chemokines are linked to cell senescence (Coppe et al., 2008; Freund et al., 2012).”
BackgroundAlarmin Detection in Senescent Cells
Kim, D., & Davalos, A. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8931-7_8 · Cited by 14
Dynamics of redox signaling in aging via autophagy, inflammation, and senescence
Javali, P. S., Sekar, M., Kumar, A., & Thirumurugan, K. (2023) · Biogerontology · doi:10.1007/s10522-023-10040-3 · Cited by 18
“SASP represents interleukins, chemokines, growth factors, MMP, ECM, NF-κB (Coppé et al.”
BackgroundInfluentialHypoxia and Hypoxia Mimetic Agents As Potential Priming Approaches to Empower Mesenchymal Stem Cells
Yasan, G. T., & ÖZCAN, A. G. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230113143234 · Cited by 18
Jayaraman, S., Eswaran, A., Rajagopal, P., Palanisamy, C. P., Veerakumar, P., Veeraraghavan, V. P., & Sirasanagandla, S. R. (2026) · Biogerontology · doi:10.1007/s10522-026-10402-7 · Cited by 44
“A new antitumor tactic is to induce senescence in cancer cells, which stops cell division and promotes the senescence-associated secretory phenotype (SASP), which attracts immune cells and inhibits the growth of neighbouring tumours (Coppe et al. 2008).”
Zhang, N., Shang, M., Li, H., Wu, L., Dong, M., Huang, B., Lü, J., & Zhang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073911 · Cited by 17
“However, studies show that tumor cell senescence induced by chemotherapeutic drugs also causes tumor recurrence by inducing SASP, which promotes cell growth and EMT [4,7,8].”
BackgroundDiniz, B. S., Seitz‐Holland, J., Sehgal, R., Kasamoto, J., Higgins‐Chen, A., & Lenze, E. J. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.09.014 · Cited by 15
Investigation of human aging at the single-cell level
Li, Y., Wang, Q., Xuan, Y., Zhao, J., Li, J., Tian, Y., Chen, G., & Tan, F. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102530 · Cited by 19
Sun, Y. (2023) · Translational Medicine of Aging · doi:10.1016/j.tma.2023.06.001 · Cited by 16
Self-citationTyphoid toxin hijacks Wnt5a to establish host senescence and Salmonella infection
ElGhazaly, M., Collins, M. O., Ibler, A. E., & Humphreys, D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113181 · Cited by 13
Single-cell transcriptomics reveals cell type diversity of human prostate
Chen, Y., Zhang, P., Liao, J., Cheng, J., Zhang, Q., Li, T., Zhang, H., Jiang, Y., Zhang, F., Zeng, Y., et al. (2022) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2022.03.009 · Cited by 12
Raats, D., Frenkel, N. C., van Schelven, S. J., Rinkes, I. H. M. B., Laoukili, J., & Kranenburg, O. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.87 · Cited by 17
Sinha, V. C., Qin, L. F., & Li, Y. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0481-t · Cited by 18
Zhu, W., Feng, D., Shi, X., Wei, Q., & Yang, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.850145 · Cited by 18
Nunes, J. M., Kell, L., Slaghekke, A., Wüst, R. C. I., Fielding, B. C., Kell, D. B., & Pretorius, E. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08162-2 · Cited by 22
“The SASP encapsulates a pro-in fl ammatory and tissue remodelling secretome [66], though its exact components depends on the cell type, mode of senescence induction (e.g., replicative, DNA damage, oncogene-induced), and stage of senescence (e.g., early, middle, or late) [68].”
Telomere dysfunction and cell cycle checkpoints in hematopoietic stem cell aging
Ju, Z., Zhang, J., Gao, Y., & Cheng, T. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0882-z · Cited by 15
“A recent study suggests that senescence-associated secretory phenotype has the ability to promote cell proliferation [ 121 ].”
BackgroundNuclear alpha-synuclein accelerates cell senescence and neurodegeneration
Du, T., Li, G., Zong, Q., Luo, H., Pan, Y., & Ma, K. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00429-0 · Cited by 16
“Senescent cells express numerous inflammatory cytokines, chemokines, and ROS [48] and contribute to age-related neurodegenerative diseases, including PD [49, 50].”
BackgroundMarzullo, M., Maï, M. E., & Ferreira, M. G. (2022) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4457 · Cited by 17
Advances in Nanotherapy for Targeting Senescent Cells
Shi, Y., Zhang, Y., Zhang, Y., Yao, J., Guo, J., Xu, X., & Wang, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s469110 · Cited by 23
Poleszczuk, J., Krzywon, A., Foryś, U., & Wideł, M. (2015) · Radiation Research · doi:10.1667/rr13907.1 · Cited by 16
“Further, SASP seems to be conserved across cell types and species, and it has been shown that SASP can be triggered after treatment of cancer patients with DNA damaging chemotherapy (18).”
BackgroundGerosuppression in confluent cells
Leontieva, O. V., & Blagosklonny, M. V. (2014) · Aging · doi:10.18632/aging.100714 · Cited by 17
The Yin-Yang of DNA Damage Response: Roles in Tumorigenesis and Cellular Senescence
Li, X., Xu, H., Chong-an, X., Lin, M., Song, X., Yi, F., Feng, Y., Coughlan, K. A., Cho, W., Kim, S. W., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022431 · Cited by 20
“Senescence is frequently accompanied with oxidative stress, altered tissue microenvironment and release of inflammatory cytokines [147,152,153].”
BackgroundFrey, B., Derer, A., Scheithauer, H., Wunderlich, R., Fietkau, R., & Gaipl, U. S. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_7 · Cited by 16
“This has been termed as senescence-associated secretory phenotype (SASP) [26].”
BackgroundInfluentialMu, X., Lin, C.-Y., Hambright, W. S., Tang, Y. M., Ravuri, S. K., Lu, A., Matre, P. R., Chen, W., Gao, X., Cui, Y., et al. (2020) · Aging · doi:10.18632/aging.202413 · Cited by 18
“A hallmark of senescent cells is the production of a senescence associated secretory phenotype (SASP) [46].”
Clinical Implications of Cellular Senescence on Wound Healing
Resnik, S. G., Egger, A. N., Abujamra, B. A., & Jozic, I. (2020) · Current Dermatology Reports · doi:10.1007/s13671-020-00320-3 · Cited by 18
Xu, M., Xia, Z.-Y., Sun, J., Liu, C., An, Y., Xu, J., Zhang, S.-H., Zhong, X., Zeng, N., Ma, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395047 · Cited by 16
Crosstalk between Lipid Rafts and Aging: New Frontiers for Delaying Aging
Zhang, S., Zhu, N., Gu, J., Li, H., Qiu, Y., Liao, D.-F., & Li, Q. (2022) · Aging and Disease · doi:10.14336/ad.2022.0116 · Cited by 16
Yao, M., Wu, Y., Cao, Y., Liu, H., Ma, N., Chai, Y., Zhang, S., Zhang, H., Nong, L., Li, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667920 · Cited by 18
Kuehnemann, C., Hu, K., Butera, K., Patel, S. K., Bons, J., Schilling, B., Aguayo‐Mazzucato, C., & Wiley, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935106 · Cited by 20
“Release of many SASP factors is restrained by the activity of p53 (41, 50), though DAMPs such as HMGB1 are released in a p53-dependent manner during senescence (51).”
BackgroundSenescent Cells in IPF: Locked in Repair?
Meiners, S., & Lehmann, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.606330 · Cited by 16
“It further aggravates inflammation and tissue fibrosis via secretion of proinflammatory and pro-fibrotic SASP (4, 21).”
BackgroundOGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1
Zhang, L., Lincheta, L. M., Samaranayake, G. J., Sharma, N., Nguyen, D. M., Tahara, Y., Kool, E. T., & Rai, P. (2021) · Redox Biology · doi:10.1016/j.redox.2020.101848 · Cited by 14
Gu, Y., Han, J., Fan, X., Xiao, H., Chen, L., Zhao, Z., & Zhang, Y. (2022) · Food & Function · doi:10.1039/d1fo04130d · Cited by 14
Autocrine IL-1β mediates the promotion of corneal neovascularization by senescent fibroblasts
Dong, M., Yang, L., Qu, M., Hu, X., Duan, H., Zhang, X., Shi, W., & Zhou, Q. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00205.2017 · Cited by 17
Ye, D., Xu, Y., Shi, Y., Ji, J., Lü, X., Chen, H., Huang, R., Lü, P., Li, Y., Cheng, L. Y., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.1.34 · Cited by 13
Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies
Dey, A. K., Banarjee, R., Boroumand, M., Rutherford, D. V., Strassheim, Q., Nyunt, T., Olinger, B., & Basisty, N. (2023) · Biology · doi:10.3390/biology12101301 · Cited by 14
“Since its original identification with proteomic arrays in 2009 [82,83], the senescence-associated secretory phenotype (SASP) has captured the attention of many as a source of biomarkers that can assess senescent cell burden.”
BackgroundThe Role of Aging in Alzheimer’s Disease
Kerchner, G. A., & Wyss‐Coray, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_7 · Cited by 17
(2019) · doi:10.1101/609438 · Cited by 15
Self-citationBiophysical investigation of the dual binding surfaces of human transcription factors FOXO4 and p53
Kim, J., Ahn, D., & Park, C. (2021) · FEBS Journal · doi:10.1111/febs.16333 · Cited by 15
“pro-inflammatory environment that affects the neighboring cells.[12-14] Unlike apoptotic cells, which are immediately removed, senescent cells are maintained for a long time, and their accumulation accelerates aging and causes senescence-associated diseases such as type II diabetes[15], osteoarthritis[16], atheroscler…”
BackgroundThe Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity
Jain, S. S., Sojo, G. B., Sun, H., Friedland, B. N., McNamara, M. E., Schmidt, M. O., & Wellstein, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137013 · Cited by 18
“…cell cycle proteins, including p16 INK4A , p14 ARF , and p21 CIP1/ Senescence induction results in the production of the senescence-associated secretory phenotype (SASP), a collection of chemokines and cytokines expressed in senescent cells including IL-6, IL-8, IL-15, CXCL1, CCL3, and others [33].”
BackgroundThe multifunctional protein CCN1/CYR61: Bridging physiology and disease
Kerek, R., Awad, J. S., Bassam, M., Hajjar, C., Ghantous, F., Rizk, K., & Rima, M. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.104969 · Cited by 14
Cell Senescence, Telomerase, and Senolytic Therapy
Fossel, M. (2019) · OBM Geriatrics · doi:10.21926/obm.geriatr.1901034 · Cited by 14
Selenoproteins and the senescence-associated epitranscriptome
Lee, M. Y., Ojeda-Britez, S., Ehrbar, D. J., Samwer, A., Begley, T. J., & Melendez, J. A. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221116592 · Cited by 16
Weis, K. E., & Raetzman, L. T. (2019) · Toxicology · doi:10.1016/j.tox.2019.152306 · Cited by 18
Lan, Y.-Y., Chang, F.-H., Tsai, J.-H., & Chang, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.006 · Cited by 15
Aronoff, J. E., & Trumble, B. C. (2025) · Evolution Medicine and Public Health · doi:10.1093/emph/eoaf010 · Cited by 17
“However, in later life, they display prolonged mTOR expression and pro-inflammatory signaling, which has been termed the senescent-associated secretory profile (SASP) [53, 63–65].”
Futami, K., Aoyama, K., Fukuda, K., Maita, M., & Katagiri, T. (2020) · Gene · doi:10.1016/j.gene.2020.145116 · Cited by 14
DNA polymerase kappa counteracts inflammation‐induced mutagenesis in multiple organs of mice
Hakura, A., Sui, H., Sonoda, J., Matsuda, T., & Nohmi, T. (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22272 · Cited by 16
“Although cellular senescence was initially regarded as a protection mechanism against carcinogenesis, it became apparent that the senescent cells secrete inflammatory mediators, thereby promoting carcinogenesis (Coppe et al., 2008).”
BackgroundThe Potent and Paradoxical Biology of Cellular Senescence in Cancer
Romesser, P. B., & Lowe, S. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-124434 · Cited by 16
Giovos, G., Yavropoulou, M. P., & Yovos, J. G. (2019) · HORMONES · doi:10.1007/s42000-019-00132-6 · Cited by 17
Sasaki, M., Kuo, F., Huang, C., Swanson, P. E., Chen, C., Chuang, J., & Yeh, M. M. (2018) · Histopathology · doi:10.1111/his.13476 · Cited by 15
B cell senescence promotes age‐related changes in oral microbiota
Mizuno, H., Kawamoto, S., Uemura, K., Park, J. H., Hori, N., Okumura, Y., Konishi, Y., & Hara, E. (2024) · Aging Cell · doi:10.1111/acel.14304 · Cited by 19
“Furthermore, senescent cells also cause senescence-associated secretory phenotypes (SASP), in which the cells secrete a variety of pro-inflammatory factors into the extracellular fluid (Acosta et al., 2008 ; Chaib et al., 2022; Coppé et al., 2008 ; Kuilman et al., 2008; Wu et al., 2024 ).”
The cGAS-STING axis: a comprehensive review from immune defense to disease pathogenesis
Sood, A. (2025) · Immunologic Research · doi:10.1007/s12026-025-09648-z · Cited by 20
Fernandes, S. E., & Saini, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.744013 · Cited by 16
“…ability to secrete several factors comprising the Senescence Associated Secretory Phenotype (SASP) that can alter its surrounding micro-environment (Coppé et al., 2008; Coppé et al., 2010), their comparatively higher resistance to apoptosis when insulted by certain stressors (Soto-gamez et al.,…”
BackgroundCholesterol drives inflammatory senescence
Kuehnemann, C., & Wiley, C. D. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00758-2 · Cited by 12
Double-strand breaks and the concept of short- and long-term epigenetic memory
Orlowski, C., Mah, L.-J., Vasireddy, R. S., El‐Osta, A., & Karagiannis, T. C. (2010) · Chromosoma · doi:10.1007/s00412-010-0305-6 · Cited by 19
Fifor, A., Krukowski, K., & Honda, J. R. (2022) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2022.100297 · Cited by 17
Marmisolle, I., Chacón, E., Mansilla, S., Ruiz, S., Bresque, M., Martínez, J., Martínez‐Zamudio, R. I., Herbig, U., Liu, J., Finkel, T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103606 · Cited by 16
“IL-8 secretion by senescent BJ skin fibroblasts was lower than in IMR-90 lung fibroblasts, in agreement with previous reports that show tissue-dependent differences in the SASP [6,38].”
Toupchian, O., Abdollahi, S., Salehi‐Abargouei, A., Heshmati, J., Clark, C. C. T., Sheikhha, M. H., Fallahzadeh, H., & Mozaffari–Khosravi, H. (2021) · Phytotherapy Research · doi:10.1002/ptr.7031 · Cited by 15
“results in the cell-cycle arrest at the S/G2 phase (Cayrol, Knibiehler, & Ducommun, 1998; Coppé et al., 2008).”
BackgroundSenescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control
Belenki, D., Richter‐Pechańska, P., Shao, Z., Bhattacharya, A., Lau, A., de Freitas, J. A. N. L. F., Kandler, G., Hick, T., Cai, X., Scharnagl, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57429-x · Cited by 16
The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress
Liu, Y., Feng, J., Yuan, K., Wu, Z., Hu, L., Lu, Y., Li, K., Guo, J., Chen, J., Ma, C., et al. (2022) · eLife · doi:10.7554/elife.69255 · Cited by 22
Zoncu, R., & Sabatini, D. M. (2011) · Science · doi:10.1126/science.1207552 · Cited by 13
Transcription-independent induction of rapid-onset senescence is integral to healing
Valdivieso, K., Rozmaric, T., Victorelli, S. G., Jadhav, V., Ring, N., Machcińska-Zielińska, S., Schädl, B., Dworak, H., Klinaki, E., Fischer, I., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01948-2 · Cited by 19
Roles of Microenvironment on Mesenchymal Stem Cells Therapy for Osteoarthritis
Zhang, H., Jin, C., Hua, J., Chen, Z., Gao, W., Xu, W., Zhou, L., & Shan, L. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s475617 · Cited by 14
“62 The functional capacity and their number of MSCs declines with age.”
BackgroundNew concept: cellular senescence in pathophysiology of cholangiocarcinoma
Sasaki, M., & Nakanuma, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1133291 · Cited by 14
Cellular Senescence is a Common Characteristic Shared by Preneoplasic and Osteo-Arthritic Tissue
Brondello, J., Philipot, D., Djouad, F., Jørgensen, C., & Noël, D. (2010) · The Open Rheumatology Journal · doi:10.2174/1874312901004010010 · Cited by 15
“In OA patients, VEGF production was shown to participate in the formation of osteophytes at the edges of articular cartilage [46].”
BackgroundInfluentialRandom mtDNA mutations modulate proliferation capacity in mouse embryonic fibroblasts
Kukat, A., Edgar, D., Bratic, I., Maiti, P., & Trifunović, A. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.145 · Cited by 15
Geroscience and the Coronavirus Pandemic: The Whack‐a‐Mole Approach is not Enough
Sierra, F. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16489 · Cited by 12
He, X., Sun, Y., Lu, J., Naz, F., Ma, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117760 · Cited by 16
Self-citationLuo, L., Lechuga‐Vieco, A. V., Sattentau, C., Borsa, M., & Simon, A. K. (2025) · EMBO Reports · doi:10.1038/s44319-025-00536-z · Cited by 16
“The release of pro-in fl ammatory cytokines also supports tumour growth and metastasis, resulting in higher susceptibility to cancers (Tato-Costa et al, 2016; Coppé et al, 2008).”
Translational Strategies to Target Metastatic Bone Disease
Pagnotti, G. M., Trivedi, T., & Mohammad, K. S. (2022) · Cells · doi:10.3390/cells11081309 · Cited by 13
Macroautophagy and the Oncogene-Induced Senescence
Grasso, D., & Vaccaro, M. I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00157 · Cited by 13
“It is believed that SASP induces some inflammatory response and the clearance of senescent cells, although it could also enhance malignancy (55, 56).”
Vulpis, E., Cuollo, L., Borrelli, C., Antonangeli, F., Masuelli, L., Cippitelli, M., Fionda, C., Caracciolo, G., Petrucci, M. T., Santoni, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076862 · Cited by 15
“is composed of several cytokines, chemokines, growth factors and proteases [9], which overall can have a profound effect on the microenvironment, promoting or repressing tumor progression in a context-dependent manner [5,22,23].”
BackgroundMiR-302a Regenerates Human Corneal Endothelial Cells against IFN-γ-Induced Cell Death
Park, S.-H., Hwang, J. S., Oh, S., & Shin, Y. J. (2022) · Cells · doi:10.3390/cells12010036 · Cited by 13
“The secretion of TNF-α and IL-6, known as the SASP factors, was amplified by IFN-γ treatment, which was eliminated by miR-302a (Figure 3A,B). mRNA expression of IL-8 and CCL2 was evaluated by real-time PCR (Figure 3C,D).”
BackgroundInfluentialRamini, D., Giuliani, A., Kwiatkowska, K. M., Guescini, M., Storci, G., Mensa’, E., Recchioni, R., Xumerle, L., Zago, E. D., Sabbatinelli, J., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01954-z · Cited by 15
“The main features of senescent cells are the loss of replicative ability and the acquisition of a secretory phenotype (SASP), characterized by the release of numerous cytokines, chemokines, and growth factors [1].”
Miyata, K., Zhou, X., Nishio, M., Hanyu, A., Chiba, M., Kawasaki, H., Osako, T., Takeuchi, K., Ohno, S., Ueno, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305046120 · Cited by 14
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.